Spots Global Cancer Trial Database for mantle cell lymphoma
Every month we try and update this database with for mantle cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor | NCT03235544 | Lymphoma | Parsaclisib | 18 Years - | Incyte Corporation | |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | NCT03842696 | Hematologic Dis... Acute Leukemia ... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Myelodysplastic... Mantle Cell Lym... Follicular Lymp... Diffuse Large B... Non Hodgkin Lym... Graft Vs Host D... Graft-versus-ho... | Vorinostat Blood and Marro... Tacrolimus (or ... Methotrexate Mycophenolate M... Cyclophosphamid... | 3 Years - 39 Years | University of Michigan Rogel Cancer Center | |
| A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | NCT01569750 | CD20-positive B... | Part 1, Cohort ... Part 1, Cohort ... Part 1, Cohort ... Part 2, Cohort ... Part 2, Cohort ... | 18 Years - | Janssen Research & Development, LLC | |
| Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | NCT01180049 | Non-Hodgkin's L... | temsirolimus temsirolimus | 18 Years - | Pfizer | |
| Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. | NCT04882475 | Mantle Cell Lym... | 18 Years - 80 Years | Fondazione Italiana Linfomi - ETS | ||
| Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | NCT00963534 | Mantle Cell Lym... | lenalidomide, b... lenalidomide, b... | 65 Years - | Lund University Hospital | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01776840 | Mantle Cell Lym... | Bendamustine Rituximab Ibrutinib Placebo | 65 Years - | Janssen Research & Development, LLC | |
| Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | NCT05025423 | Mantle Cell Lym... | Venetoclax Oral... | 60 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) | NCT00505232 | Mantle Cell Lym... | Y-90 Ibritumoma... | 18 Years - 70 Years | CABYC | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | NCT01472562 | Mantle Cell Lym... | lenalidomide rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma | NCT02840539 | Mantle Cell Lym... | Bortezomib, Cyt... | 18 Years - | Seoul National University Hospital | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | NCT02819583 | Acute Lymphocyt... Chronic Lymphoc... Follicular Lymp... Mantle Cell Lym... B-cell Prolymph... Diffuse Large C... | PCAR-019 (anti-... | 18 Years - | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma | NCT00980395 | Lymphoma Mantle Cell Lym... Indolent Lympho... SLL | rituximab bortezomib cladribine | 18 Years - | University of Arizona | |
| Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | NCT01851551 | Non-Hodgkin's L... Diffuse Large B... Mantle Cell Lym... | Vincristine Sul... | 18 Years - | Acrotech Biopharma Inc. | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL | NCT01449344 | Mantle Cell Lym... | Rituximab High dose Ara-C Dexamethasone Bortezomib | 18 Years - | European Mantle Cell Lymphoma Network | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03019640 | Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo... | Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab | 15 Years - 70 Years | M.D. Anderson Cancer Center | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma | NCT01933711 | CD20+ Aggressiv... | rituximab | 18 Years - | University Hospital Heidelberg | |
| Lenalidomide and R-CHOP in B-cell Lymphoma | NCT00901615 | Lymphoma, Large... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | Lenalidomide an... | 18 Years - 70 Years | Lymphoma Study Association | |
| A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | NCT01599949 | Mantle Cell Lym... | Ibrutinib | 18 Years - | Janssen Research & Development, LLC | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 | NCT02507336 | Mantle Cell Lym... Non-Hodgkin's L... | Thalidomide | 18 Years - | University of Miami | |
| Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | NCT02238522 | Lymphoprolifera... Acute Myeloid L... | ZEN003365 | 18 Years - | Zenith Epigenetics | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) | NCT00607854 | Diffuse Large B... Mantle Cell Lym... | Ibritumomab Tiu... | 18 Years - 65 Years | University Hospital, Bordeaux | |
| Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant | NCT01244906 | Hematologic Neo... | Allogeneic Hema... | 18 Years - 75 Years | Northside Hospital, Inc. | |
| The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma | NCT03016988 | Mantle Cell Lym... | Bortezomib Fludarabine Cytarabine | 18 Years - 75 Years | Fujian Medical University | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma | NCT04918940 | Follicular Lymp... Mantle Cell Lym... | Determination o... | 18 Years - | Centre Henri Becquerel | |
| Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma | NCT01078142 | Follicular Lymp... Mantle Cell Lym... | Temsirolimus, R... | 18 Years - | Johannes Gutenberg University Mainz | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Zevalin Post-marketing Surveillance in Japan | NCT01448928 | Non-Hodgkin's L... | [90]Y-ibritumom... | - | Spectrum Pharmaceuticals, Inc | |
| Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | NCT01345357 | Solid Tumors or... | CEP-9722 Gemcitabine Cisplatin | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Ublituximab + Ibrutinib in Select B-cell Malignancies | NCT02013128 | Chronic Lymphoc... Mantle Cell Lym... | Ublituximab Ibrutinib | 18 Years - | TG Therapeutics, Inc. | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | NCT06263491 | Mantle Cell Lym... | Rituximab Pirtobrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | NCT01399840 | Acute Myeloid L... Myelodysplastic... Chronic Lymphoc... Mantle Cell Lym... | BMN 673 | 18 Years - | Pfizer | |
| Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | NCT03232307 | CCND1 Positive CD20-Positive N... Mantle Cell Lym... | Dexamethasone Ibrutinib Lenalidomide Rituximab | 66 Years - | M.D. Anderson Cancer Center | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients | NCT03028103 | Diffuse Large B... Primary Mediast... Mantle Cell Lym... Advanced Solid ... Marginal Zone L... | Tazemetostat Fluconazole Omeprazole Repaglinide | 18 Years - | Ipsen | |
| FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | NCT05934097 | Diffuse Large B... Transformed Ind... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | FT596 Cyclophosphamid... Doxorubicin Vincristine Prednisone Rituximab Bendamustine | 18 Years - | Fate Therapeutics | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT03410901 | B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... | Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| Study of Mantle Cell Lymphoma Treatment by RiBVD | NCT01457144 | Mantle Cell Lym... | RiBVD | 65 Years - 85 Years | French Innovative Leukemia Organisation | |
| Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | NCT03939182 | Diffuse Large B... Mantle Cell Lym... | Abexinostat Ibrutinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | NCT02356458 | Mantle Cell Lym... | Ibrutinib bortezomib | 18 Years - | Swiss Group for Clinical Cancer Research | |
| MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | NCT01397825 | Diffuse Large B... Transformed Fol... Mantle Cell Lym... Burkitt's Lymph... | Alisertib (MLN8... Rituximab Vincristine | 18 Years - | Takeda | |
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma | NCT00445341 | Lymphoma | Flavopiridol | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | NCT03410901 | B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... | Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | NCT02927964 | Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Folli... Refractory Foll... Mantle Cell Lym... Marginal Zone L... | Ibrutinib Radiation Thera... TLR9 Agonist SD... | 18 Years - | Stanford University | |
| A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | NCT06341556 | Mantle Cell Lym... Maintenance The... | Zanubrutinib | 18 Years - | Fudan University | |
| A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | NCT02972840 | Lymphoma, Mantl... | Acalabrutinib Bendamustine Rituximab Placebo | 65 Years - | Acerta Pharma BV | |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | NCT03834688 | Mantle Cell Lym... | Venetoclax Bendamustine Rituximab | 60 Years - | PrECOG, LLC. | |
| Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | NCT03616782 | Mantle Cell Lym... | Ixazomib | 19 Years - | Kosin University Gospel Hospital | |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | NCT03676504 | Acute Lymphobla... Acute Lymphobla... Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... | CD19.CAR T Cell... Fludarabine Cyclophosphamid... | 3 Years - | University Hospital Heidelberg | |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma | NCT04626791 | Mantle Cell Lym... | Acalabrutinib Bortezomib Cyclophosphamid... Cytarabine Doxorubicin Hyd... Prednisone Rituximab Rituximab and H... | 18 Years - 75 Years | Academic and Community Cancer Research United | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | NCT04783415 | Mantle Cell Lym... | Acalabrutinib Ublituximab Umbralisib | 18 Years - | City of Hope Medical Center | |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma | NCT01786135 | Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel... | SGN-CD19A | 12 Years - | Seagen Inc. | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | NCT04082936 | Non-Hodgkin Lym... Follicular Lymp... DLBCL Mantle Cell Lym... Marginal Zone L... | imvotamab | 18 Years - | IGM Biosciences, Inc. | |
| Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | NCT01239875 | Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Adult Diffuse M... Adult Diffuse S... Adult Grade III... Adult Immunobla... Adult Lymphobla... Grade 1 Follicu... Grade 2 Follicu... Grade 3 Follicu... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Splenic Margina... Waldenstrom Mac... | dendritic cell ... cryotherapy pneumococcal po... laboratory biom... immunoenzyme te... immunohistochem... autologous dend... | 18 Years - 90 Years | Mayo Clinic | |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | NCT03999697 | Diffuse Large B... Follicular Lymp... Primary Cutaneo... Extranodal Marg... Mantle Cell Lym... Plasma Cell Neo... B Cell Lymphoma | Autologous chim... | 3 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | NCT05458297 | Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Richter Transfo... | Zilovertamab ve... Nemtabrutinib | 18 Years - | Merck Sharp & Dohme LLC | |
| EDOCH Alternating With DHAP for New Diagnosed Younger MCL | NCT02858804 | Mantle Cell Lym... | Etoposide Doxorubicin Dexamethasone Vincristine Cyclophosphamid... Cytarabine Cisplatin Rituximab Thalidomide Prednisone | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
